TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effectiveness of Neurodynamic Techniques in Patients With Nerve-Related Leg Pain
Brief Summary: This study aims to verify if patients with nerve-related leg pain benefits from neurodynamic treatment over two weeks.


Options:
A: Arm Label: Sensorimotor; Type: EXPERIMENTAL; Interventions: Other: Proprioceptive postural training, Other: Conventional physiotherapy | Arm Label: Low-intensity activity; Type: ACTIVE_COMPARATOR; Interventions: Other: Treadmill training, Other: Conventional physiotherapy | Intervention Type: OTHER; Name: Proprioceptive postural training; Assigned to Arm(s): Sensorimotor | Intervention Type: OTHER; Name: Treadmill training; Assigned to Arm(s): Low-intensity activity | Intervention Type: OTHER; Name: Conventional physiotherapy; Assigned to Arm(s): Low-intensity activity, Sensorimotor
B: Arm Label: RESTORE Intervention; Type: EXPERIMENTAL; Interventions: Other: RESTORE Intervention | Arm Label: Control Group 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: RESTORE Intervention; Assigned to Arm(s): RESTORE Intervention
C: Arm Label: Neurodynamic group; Type: EXPERIMENTAL; Interventions: Procedure: Neurodynamic Group | Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Neurodynamic Group; Assigned to Arm(s): Neurodynamic group
D: Intervention Type: BEHAVIORAL; Name: Supervised Nordic Walking; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Unsupervised Nordic Walking; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Advice to stay active; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multi-centred, Stepped Wedge, Cluster Randomised Controlled Trial to Compare the Clinical and Cost Effectiveness of a Complex Oral Health Care Intervention and Standard Oral Health Care in Stroke Care Settings: a Phase II Pilot Trial.
Brief Summary: Stroke associated pneumonia (SAP) affects a fifth of stroke survivors annually, tripling the risk of death at 30 days and contributing to poorer rehabilitation outcomes, prolonged hospital stays and dependency at discharge. Systematic review evidence indicates that enhanced oral health care (OHC) has a preventative effect on the incidence of pneumonia amongst nursing home populations (absolute risk reductions 6.6% to 11.7%; numbers needed to treat 8.6 to 15.3 individuals). There are strong theoretical reasons to suggest similar benefits might be observed in stroke care settings but current empirical evidence is weak - trial quality (randomisation, blinding, sample size, reporting), intervention description and thus feasibility of translation into clinical practice is very poor. Following an extensive pre-clinical programme of work, investigators now plan the pilot phase (Phase II) of a stepped-wedge cluster RCT of a well-developed and defined complex OHC intervention versus usual OHC. Investigators aim to establish a robust web-based randomisation process, refine the proposed intervention (training, tools, equipment), recruitment, adherence, record linkage and sampling methodologies. Investigators also aim to establish the relationship between SAP and plaque and any diversity between sites.


Options:
A: Arm Label: Improvement intervention; Type: OTHER; Interventions: Behavioral: improvement intervention | Arm Label: no intervention; Type: OTHER; Interventions: Behavioral: no intervention | Intervention Type: BEHAVIORAL; Name: improvement intervention; Assigned to Arm(s): Improvement intervention | Intervention Type: BEHAVIORAL; Name: no intervention; Assigned to Arm(s): no intervention
B: Arm Label: Pre-intervention group (Control group); Type: N/A; Interventions: N/A | Arm Label: Post-intervention group (Training course group); Type: N/A; Interventions: Other: training of emergency professionals to acute stroke management | Intervention Type: OTHER; Name: training of emergency professionals to acute stroke management; Assigned to Arm(s): Post-intervention group (Training course group)
C: Arm Label: Intervention; Type: OTHER; Interventions: Other: Implementation of stroke mobility guidelines | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Implementation of stroke mobility guidelines; Assigned to Arm(s): Intervention
D: Arm Label: Enhanced complex oral health care intervention; Type: EXPERIMENTAL; Interventions: Other: Enhanced complex oral health care | Arm Label: Usual oral health care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Enhanced complex oral health care; Assigned to Arm(s): Enhanced complex oral health care intervention

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multi-centred, Stepped Wedge, Cluster Randomised Controlled Trial to Compare the Clinical and Cost Effectiveness of a Complex Oral Health Care Intervention and Standard Oral Health Care in Stroke Care Settings: a Phase II Pilot Trial.
Brief Summary: Stroke associated pneumonia (SAP) affects a fifth of stroke survivors annually, tripling the risk of death at 30 days and contributing to poorer rehabilitation outcomes, prolonged hospital stays and dependency at discharge. Systematic review evidence indicates that enhanced oral health care (OHC) has a preventative effect on the incidence of pneumonia amongst nursing home populations (absolute risk reductions 6.6% to 11.7%; numbers needed to treat 8.6 to 15.3 individuals). There are strong theoretical reasons to suggest similar benefits might be observed in stroke care settings but current empirical evidence is weak - trial quality (randomisation, blinding, sample size, reporting), intervention description and thus feasibility of translation into clinical practice is very poor. Following an extensive pre-clinical programme of work, investigators now plan the pilot phase (Phase II) of a stepped-wedge cluster RCT of a well-developed and defined complex OHC intervention versus usual OHC. Investigators aim to establish a robust web-based randomisation process, refine the proposed intervention (training, tools, equipment), recruitment, adherence, record linkage and sampling methodologies. Investigators also aim to establish the relationship between SAP and plaque and any diversity between sites.


Options:
A: Arm Label: povidone iodine; Type: EXPERIMENTAL; Interventions: Drug: povidone iodine | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: povidone iodine; Assigned to Arm(s): povidone iodine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): placebo
B: Arm Label: OHI; Type: EXPERIMENTAL; Interventions: Other: Oral hygiene intervention | Arm Label: OHI + CHX mouthrinse; Type: EXPERIMENTAL; Interventions: Other: Oral hygiene intervention | Arm Label: OHI + CHX mouthrinse + assisted brushing; Type: EXPERIMENTAL; Interventions: Other: Oral hygiene intervention | Intervention Type: OTHER; Name: Oral hygiene intervention; Assigned to Arm(s): OHI, OHI + CHX mouthrinse, OHI + CHX mouthrinse + assisted brushing
C: Arm Label: Enhanced complex oral health care intervention; Type: EXPERIMENTAL; Interventions: Other: Enhanced complex oral health care | Arm Label: Usual oral health care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Enhanced complex oral health care; Assigned to Arm(s): Enhanced complex oral health care intervention
D: Arm Label: enhanced oral care; Type: EXPERIMENTAL; Interventions: Other: Enhanced Oral Care | Arm Label: Usual care; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual oral care | Intervention Type: OTHER; Name: Enhanced Oral Care; Assigned to Arm(s): enhanced oral care | Intervention Type: OTHER; Name: Usual oral care; Assigned to Arm(s): Usual care

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With GSK Biologicals' Seasonal Influenza Vaccine GSK2321138A in Adults Aged 50 Years and Older
Brief Summary: The purpose of this study is to assess immunogenicity, reactogenicity and safety of GSK Biologicals' HZ/su vaccine when its first dose is co-administered with the FLU-D-QIV vaccine in adults aged 50 years or older compared to administration of vaccines separately.


Options:
A: Arm Label: Co-Ad Group; Type: EXPERIMENTAL; Interventions: Biological: Herpes Zoster vaccine GSK 1437173A, Biological: GSK Biologicals' quadrivalent seasonal influenza vaccine FLU-D-QIV GSK2321138A | Arm Label: Control Group; Type: ACTIVE_COMPARATOR; Interventions: Biological: Herpes Zoster vaccine GSK 1437173A, Biological: GSK Biologicals' quadrivalent seasonal influenza vaccine FLU-D-QIV GSK2321138A | Intervention Type: BIOLOGICAL; Name: Herpes Zoster vaccine GSK 1437173A; Assigned to Arm(s): Co-Ad Group, Control Group | Intervention Type: BIOLOGICAL; Name: GSK Biologicals' quadrivalent seasonal influenza vaccine FLU-D-QIV GSK2321138A; Assigned to Arm(s): Co-Ad Group, Control Group
B: Arm Label: Zoster vaccine group; Type: EXPERIMENTAL; Interventions: Biological: Herpes Zoster Vaccine GSK1437173A | Arm Label: Placebo group; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: Herpes Zoster Vaccine GSK1437173A; Assigned to Arm(s): Zoster vaccine group | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo group
C: Arm Label: GSK1437173A formulation 1 Group; Type: EXPERIMENTAL; Interventions: Biological: Herpes zoster vaccine GSK1437173A | Arm Label: GSK1437173A formulation 2 Group; Type: EXPERIMENTAL; Interventions: Biological: Herpes zoster vaccine GSK1437173A | Arm Label: GSK1437173A formulation 3 Group; Type: EXPERIMENTAL; Interventions: Biological: Herpes zoster vaccine GSK1437173A | Arm Label: Control Group; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: Herpes zoster vaccine GSK1437173A; Assigned to Arm(s): GSK1437173A formulation 1 Group, GSK1437173A formulation 2 Group, GSK1437173A formulation 3 Group | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Control Group
D: Arm Label: GSK1437173A Group; Type: EXPERIMENTAL; Interventions: Biological: GSK Biologicals Herpes Zoster subunit (HZ/su) vaccine (GSK 1437173A) | Arm Label: Control Group; Type: ACTIVE_COMPARATOR; Interventions: Biological: GSK Biologicals Herpes Zoster subunit (HZ/su) vaccine (GSK 1437173A) | Intervention Type: BIOLOGICAL; Name: GSK Biologicals Herpes Zoster subunit (HZ/su) vaccine (GSK 1437173A); Assigned to Arm(s): Control Group, GSK1437173A Group

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effect of an Enhanced Dietary Portfolio Plus Exercise on Cardiovascular Risk in High Risk Individuals.
Brief Summary: "Is it possible to recruit and retain up to 200 participants in a Randomize Control Trial (RCT) of high impact lifestyle approach of diet and exercise designed to significantly reduce cardiovascular events in middle-aged and older men and women at high risk of such events?" To address this question, we propose a pilot study of 3 years in duration: 1 year recruitment and randomization, a full year of intervention for all recruited participants, and the last 6 months to assess the one year data and prepare and submit the full trial application, informed by the pilot study outcomes in terms of retention rate. The pilot will then continue on for the full 9 years of intervention and be rolled into the main study involving additional Canadian centers and collaborating international centers in the US, Britain, Europe, Australia, New Zealand, India, and South Africa.


Options:
A: Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: intervention group; Type: EXPERIMENTAL; Interventions: Dietary Supplement: artificially sweetened beverages | Intervention Type: DIETARY_SUPPLEMENT; Name: artificially sweetened beverages; Assigned to Arm(s): intervention group
B: Arm Label: Enhanced Portfolio plus structured exercise; Type: EXPERIMENTAL; Interventions: Behavioral: Enhanced portfolio plus structured exercise | Arm Label: High fiber diet plus routine exercise; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: High fiber diet plus routine exercise | Intervention Type: BEHAVIORAL; Name: Enhanced portfolio plus structured exercise; Assigned to Arm(s): Enhanced Portfolio plus structured exercise | Intervention Type: BEHAVIORAL; Name: High fiber diet plus routine exercise; Assigned to Arm(s): High fiber diet plus routine exercise
C: Arm Label: Sucrose; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Sucrose | Arm Label: Aspartame; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Aspartame | Intervention Type: DIETARY_SUPPLEMENT; Name: Sucrose; Assigned to Arm(s): Sucrose | Intervention Type: DIETARY_SUPPLEMENT; Name: Aspartame; Assigned to Arm(s): Aspartame
D: Intervention Type: BEHAVIORAL; Name: diet, sodium-restricted; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: diet, fat-restricted; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: exercise; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: diet, reducing; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: alcohol drinking; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effect of an Enhanced Dietary Portfolio Plus Exercise on Cardiovascular Risk in High Risk Individuals.
Brief Summary: "Is it possible to recruit and retain up to 200 participants in a Randomize Control Trial (RCT) of high impact lifestyle approach of diet and exercise designed to significantly reduce cardiovascular events in middle-aged and older men and women at high risk of such events?" To address this question, we propose a pilot study of 3 years in duration: 1 year recruitment and randomization, a full year of intervention for all recruited participants, and the last 6 months to assess the one year data and prepare and submit the full trial application, informed by the pilot study outcomes in terms of retention rate. The pilot will then continue on for the full 9 years of intervention and be rolled into the main study involving additional Canadian centers and collaborating international centers in the US, Britain, Europe, Australia, New Zealand, India, and South Africa.


Options:
A: Arm Label: Lifestyle Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Lifestyle Intervention | Arm Label: Diabetes Support and Education; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Diabetes Support and Education | Intervention Type: BEHAVIORAL; Name: Lifestyle Intervention; Assigned to Arm(s): Lifestyle Intervention | Intervention Type: BEHAVIORAL; Name: Diabetes Support and Education; Assigned to Arm(s): Diabetes Support and Education
B: Arm Label: Enhanced Portfolio plus structured exercise; Type: EXPERIMENTAL; Interventions: Behavioral: Enhanced portfolio plus structured exercise | Arm Label: High fiber diet plus routine exercise; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: High fiber diet plus routine exercise | Intervention Type: BEHAVIORAL; Name: Enhanced portfolio plus structured exercise; Assigned to Arm(s): Enhanced Portfolio plus structured exercise | Intervention Type: BEHAVIORAL; Name: High fiber diet plus routine exercise; Assigned to Arm(s): High fiber diet plus routine exercise
C: Arm Label: High MUFA diet; Type: EXPERIMENTAL; Interventions: Other: High-MUFA diet | Arm Label: High CHO diet; Type: ACTIVE_COMPARATOR; Interventions: Other: High-CHO diet | Intervention Type: OTHER; Name: High-MUFA diet; Assigned to Arm(s): High MUFA diet | Intervention Type: OTHER; Name: High-CHO diet; Assigned to Arm(s): High CHO diet
D: Intervention Type: BEHAVIORAL; Name: Diet counseling; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Clinical Evaluation of the Efficacy of Methylnaltrexone in Resolving Constipation Induced by Different Opioid Subtypes, Combined With Laboratory Analysis of Immunomodulatory and Antiangiogenic Effects of Methylnaltrexone
Brief Summary: Methylnaltrexone for the treatment of opioid-induced constipation in the setting of palliative or hospice care, is significantly more effective than placebo (1). However, in both the randomized and the open-label phase of the multi center trial showing this favorable outcome, the drug produced rescue-free laxation in only about half of the patients (2). There may be several reasons for this result, since constipation in palliative care patients often has multiple simultaneously occurring causes.

Assuming that constipation of the non-responders is still opioid-induced, one of the possible reasons for not responding to methylnaltrexone could be that central actions of opioids contribute to constipation by reducing motility of the intestines through direct actions in the spinal dorsal horn (2). However, as methylnaltrexone is a µ-receptor antagonist and not all opioids are solely µ-receptor agonists another reason may well be that successful laxation is determined by the receptor-profile of the specific opioid the patient is using.

Opioids do not only influence bowel functioning, but also immune system functioning and angiogenesis. Methylnaltrexone possibly antagonizes these changes, therefore this study will also investigate the influence of methylnaltrexone on immunologic and angiogenic parameters.


Options:
A: Arm Label: Morphine Sulphate; Type: N/A; Interventions: Drug: methylnaltrexone | Arm Label: Fentanyl; Type: N/A; Interventions: Drug: methylnaltrexone | Arm Label: Oxycodone; Type: N/A; Interventions: Drug: methylnaltrexone | Intervention Type: DRUG; Name: methylnaltrexone; Assigned to Arm(s): Fentanyl, Morphine Sulphate, Oxycodone
B: Arm Label: Methylnaltrexone bromide; Type: EXPERIMENTAL; Interventions: Drug: Methylnaltrexone bromide | Intervention Type: DRUG; Name: Methylnaltrexone bromide; Assigned to Arm(s): Methylnaltrexone bromide
C: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: SC Methylnaltrexone | Arm Label: Arm 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: SC Placebo | Arm Label: Arm 2; Type: EXPERIMENTAL; Interventions: Drug: SC Methylnaltrexone | Intervention Type: DRUG; Name: SC Methylnaltrexone; Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: SC Placebo; Assigned to Arm(s): Arm 3 | Intervention Type: DRUG; Name: SC Methylnaltrexone; Assigned to Arm(s): Arm 2
D: Arm Label: Targinact® (oxycodon/naloxon); Type: N/A; Interventions: Drug: Targinact® (oxycodon/naloxon) | Intervention Type: DRUG; Name: Targinact® (oxycodon/naloxon); Assigned to Arm(s): Targinact® (oxycodon/naloxon)

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Clinical Evaluation of the Efficacy of Methylnaltrexone in Resolving Constipation Induced by Different Opioid Subtypes, Combined With Laboratory Analysis of Immunomodulatory and Antiangiogenic Effects of Methylnaltrexone
Brief Summary: Methylnaltrexone for the treatment of opioid-induced constipation in the setting of palliative or hospice care, is significantly more effective than placebo (1). However, in both the randomized and the open-label phase of the multi center trial showing this favorable outcome, the drug produced rescue-free laxation in only about half of the patients (2). There may be several reasons for this result, since constipation in palliative care patients often has multiple simultaneously occurring causes.

Assuming that constipation of the non-responders is still opioid-induced, one of the possible reasons for not responding to methylnaltrexone could be that central actions of opioids contribute to constipation by reducing motility of the intestines through direct actions in the spinal dorsal horn (2). However, as methylnaltrexone is a µ-receptor antagonist and not all opioids are solely µ-receptor agonists another reason may well be that successful laxation is determined by the receptor-profile of the specific opioid the patient is using.

Opioids do not only influence bowel functioning, but also immune system functioning and angiogenesis. Methylnaltrexone possibly antagonizes these changes, therefore this study will also investigate the influence of methylnaltrexone on immunologic and angiogenic parameters.


Options:
A: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: SC Methylnaltrexone | Arm Label: Arm 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: SC Placebo | Arm Label: Arm 2; Type: EXPERIMENTAL; Interventions: Drug: SC Methylnaltrexone | Intervention Type: DRUG; Name: SC Methylnaltrexone; Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: SC Placebo; Assigned to Arm(s): Arm 3 | Intervention Type: DRUG; Name: SC Methylnaltrexone; Assigned to Arm(s): Arm 2
B: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: SC Methylnaltrexone | Arm Label: Arm 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: SC Placebo | Intervention Type: DRUG; Name: SC Methylnaltrexone; Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: SC Placebo; Assigned to Arm(s): Arm 2
C: Arm Label: Morphine Sulphate; Type: N/A; Interventions: Drug: methylnaltrexone | Arm Label: Fentanyl; Type: N/A; Interventions: Drug: methylnaltrexone | Arm Label: Oxycodone; Type: N/A; Interventions: Drug: methylnaltrexone | Intervention Type: DRUG; Name: methylnaltrexone; Assigned to Arm(s): Fentanyl, Morphine Sulphate, Oxycodone
D: Arm Label: Oxycodone Hydrochloride Tablets; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oxycodone | Arm Label: Oxycodone Naloxone Tablets; Type: EXPERIMENTAL; Interventions: Drug: Oxycodone/Naloxone | Intervention Type: DRUG; Name: Oxycodone; Assigned to Arm(s): Oxycodone Hydrochloride Tablets | Intervention Type: DRUG; Name: Oxycodone/Naloxone; Assigned to Arm(s): Oxycodone Naloxone Tablets

Answer: C